StockData
Lipocine Inc. logo

Lipocine Inc. (LPCN) stock

LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3042% below fair value
$1.52−0.08 (-5.00%)

Close on Nov 18, 2026Market cap $12.53MP/E –Yield –

Lipocine net income

Net income is the profit left for shareholders after every expense, interest and tax.

Lipocine's net income for the twelve months ending Jun 30, 2026 was -$11.85M. For fiscal 2025 it was -$9.63M, down 115371.9% from the year before. The highest annual figure on record is $3.89M in fiscal 2012.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$9.63M-115371.9%
FY2024Dec 31, 2024$8.35K–
FY2023Dec 31, 2023-$16.35M–
FY2022Dec 31, 2022-$10.76M–
FY2021Dec 31, 2021-$634.40K–
FY2020Dec 31, 2020-$20.96M–
FY2019Dec 31, 2019-$13.01M–
FY2018Dec 31, 2018-$11.66M–
FY2017Dec 31, 2017-$20.98M–
FY2016Dec 31, 2016-$18.97M–
FY2015Dec 31, 2015-$18.21M–
FY2014Dec 31, 2014-$20.37M–
FY2013Dec 31, 2013-$10.59M-372.5%
FY2012Dec 31, 2012$3.89M–
FY2011Dec 31, 2011-$5.16K–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.62M–
Q1 FY2026Mar 31, 2026-$3.67M–
Q4 FY2025Dec 31, 2025-$2.37M-233.0%
Q3 FY2025Sep 30, 2025-$3.19M–
Q2 FY2025Jun 30, 2025-$2.21M–
Q1 FY2025Mar 31, 2025-$1.86M-153.1%
Q4 FY2024Dec 31, 2024$1.78M–
Q3 FY2024Sep 30, 2024-$2.22M–
Q2 FY2024Jun 30, 2024-$3.07M–
Q1 FY2024Mar 31, 2024$3.51M–
Q4 FY2023Dec 31, 2023-$2.28M–
Q3 FY2023Sep 30, 2023-$6.65M–
Q2 FY2023Jun 30, 2023-$3.55M–
Q1 FY2023Mar 31, 2023-$3.87M–
Q4 FY2022Dec 31, 2022-$2.23M-117.7%
Q3 FY2022Sep 30, 2022-$2.41M–
Q2 FY2022Jun 30, 2022-$2.63M–
Q1 FY2022Mar 31, 2022-$3.49M–
Q4 FY2021Dec 31, 2021$12.62M–
Q3 FY2021Sep 30, 2021-$3.08M–
Q2 FY2021Jun 30, 2021-$6.81M–
Q1 FY2021Mar 31, 2021-$3.37M–
Q4 FY2020Dec 31, 2020-$4.51M–
Q3 FY2020Sep 30, 2020-$4.31M–
Q2 FY2020Jun 30, 2020-$6.37M–
Q1 FY2020Mar 31, 2020-$5.77M–
Q4 FY2019Dec 31, 2019-$3.29M–
Q3 FY2019Sep 30, 2019-$3.06M–
Q2 FY2019Jun 30, 2019-$3.43M–
Q1 FY2019Mar 31, 2019-$3.22M–
Q4 FY2018Dec 31, 2018-$3.23M–
Q3 FY2018Sep 30, 2018-$2.46M–
Q2 FY2018Jun 30, 2018-$3.26M–
Q1 FY2018Mar 31, 2018-$2.72M–
Q4 FY2017Dec 31, 2017-$5.33M–
Q3 FY2017Sep 30, 2017-$4.70M–
Q2 FY2017Jun 30, 2017-$6.09M–
Q1 FY2017Mar 31, 2017-$4.86M–
Q4 FY2016Dec 31, 2016-$2.97M–
Q3 FY2016Sep 30, 2016-$3.24M–

More Lipocine figures

See a number that looks wrong?